FDA Pharmacogenomic Submissions Final Guidance To Be Issued In March
This article was originally published in The Pink Sheet Daily
Executive Summary
The guidance has cleared the agency's Office of the Chief Counsel, FDA's Lawrence Lesko tells the Drug Information Association meeting in Lisbon, Portugal. FDA will launch a pharmacogenomics website the week of March 14 that will include information on "what's going on with voluntary submissions," Lesko says.
You may also be interested in...
Pharmacogenomics Public Workshop Planned For April 2005
The meeting will follow release of an FDA draft guidance on the co-development of pharmacogenomic tests with a drug or biologic, which is expected by the end of the year.
GSK's Nucala Is Significantly Overpriced, ICER Draft Report Finds
New biologic for severe asthma doesn't stack up well to standard of care on generally accepted levels of cost per quality-adjusted life year.
Deal Watch: Sanofi, Boehringer Swap Side Businesses
Busy week for AstraZeneca sees buyout of Acerta and acquisition of remaining Daliresp/Daxas worldwide rights from Takeda. Amgen and GSK undo their cancer drug alliances from 2009 and 2010, with all rights reverting to the big biotech.